8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 6, 2025)

Filed February 6, 2025For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 6, 2025, to announce its financial results for the fourth quarter and full year of 2024. The filing includes a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance. This report also references a supplemental presentation available on the company's website, offering further insights into financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial measures, with reconciliations provided in the press release. This 8-K serves as a notification and furnishing of material information, rather than a definitive filing with liabilities under Section 18 of the Exchange Act, for the information furnished under Item 7.01. The company's decision to make the presentation available on its website is subject to change. Investors seeking detailed financial performance, strategic updates, and forward-looking statements will find the most crucial information within the furnished press release and presentation materials.

Key Highlights

  • 1BMY filed an 8-K on February 6, 2025, announcing Q4 and full-year 2024 financial results.
  • 2The report includes a press release (Exhibit 99.1) containing detailed financial and operational information for the reported periods.
  • 3A supplemental presentation (Exhibit 99.2) on financial and operating initiatives is also furnished and available on the company's website.
  • 4Both the press release and presentation reference non-GAAP financial information, with reconciliations provided in the press release.
  • 5The information furnished under Item 7.01 is not considered 'filed' for Section 18 of the Exchange Act purposes.
  • 6Investors should refer to Exhibit 99.1 and Exhibit 99.2 for the most pertinent financial and operational disclosures.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide investors with Bristol-Myers Squibb Company's financial results for the fourth quarter and full year of 2024, along with related financial and operational initiatives.

The detailed financial results are primarily found in the press release (Exhibit 99.1) that is furnished as part of this 8-K filing. A supplemental presentation (Exhibit 99.2) also provides additional context on financial and operating initiatives.

Yes, both the earnings press release and the company presentation reference non-GAAP financial information. Reconciliations between these non-GAAP measures and the comparable GAAP financial measures are available within the furnished earnings press release (Exhibit 99.1).

The information furnished under Item 7.01 of this 8-K, including Exhibits 99.1 and 99.2, is generally not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities thereof, unless specifically incorporated by reference into future filings.